Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.01.003Source: DataRank Database

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2021). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

1 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.13)OA: closedTopics (24)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Jan Philipp Bewersdorf ORCID,David M. Swoboda ORCID,Wei Wei ORCID,Lohith Gowda,Thomas Prébet ORCID

Live enrichment

PubMed:33551344 OpenAlex:https://openalex.org/W3120684629

National Institutes of Health

Grant: P30 CA016359

Celgene

Pfizer

Frederick A. DeLuca Foundation

National Cancer Institute

Boehringer Ingelheim

AbbVie

Takeda Pharmaceuticals U.S.A.

FWCI

0.13

Citation Percentile

0.4%

Citation Trend

2022

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S2152265021000033?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265021000033?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2021.01.003

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33551344

Fields of Study

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentAgedAged, 80 and overHumansImmune Checkpoint InhibitorsMiddle AgedMyeloproliferative Disorders

MeSH Terms

Immune Checkpoint InhibitorsAgedAged, 80 and overHumansMiddle AgedMyeloproliferative Disorders

Keywords

MedicineMyeloidProgrammed cell death 1Immune checkpointImmunotherapyOncologyImmune systemImmunologyPD-L1

Sustainable Development Goals

SDG 0: Good health and well-being

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

FAIR Checklist

Authors (15)

Funding (8 grants)

Impact

Open Access

Topics